Every 10-ng/mL increase in serum 25-hydroxyvitamin D was associated with a 12% decrease in the risk for depression in older adults.
Ketamine is gaining ground as a promising option for treatment-resistant depression, but not every clinician is buying in. We review clinical evidence and concerns surrounding the drug.
Researchers completed a comprehensive meta-analysis examining existing literature to study the relationship between alopecia areata, anxiety, and depression.
Benzodiazepine monotherapy continues to be used to treat depression despite American Psychiatric Association guidelines, and even in cases of concomitant opioid use.
Participants of a cognitive behavioral health-based online intervention showed reduced symptoms of anxiety and depression and high levels of satisfaction in both a routine healthcare setting and a controlled research study.
Researchers investigated the validity of the Norwegian versions of the GDS-5 and HADS-D assessment tools among home-dwelling individuals aged 60 years or older.
Women with eating disorders experience persistently greater depressive symptoms across the life-course.
Anxiety and stress-related phenotypes correlated with such traits as depression and obesity and smoking.
Adult patients with treatment-resistant depression showed a favorable improvement in symptoms after a course of esketamine twice-weekly for 28 days.
The Drug Enforcement Administration (DEA) has placed Zulresso (brexanolone; Sage Therapeutics), a treatment for postpartum depression, into Schedule IV of the Controlled Substances Act.